Large-scale real-world data analysis identifies comorbidity patterns in schizophrenia

被引:0
作者
Chenyue Lu
Di Jin
Nathan Palmer
Kathe Fox
Isaac S. Kohane
Jordan W. Smoller
Kun-Hsing Yu
机构
[1] Harvard Medical School,Department of Biomedical Informatics
[2] Massachusetts Institute of Technology,Computer Science and Artificial Intelligence Laboratory
[3] Massachusetts General Hospital,Department of Psychiatry
[4] Harvard T.H. Chan School of Public Health,Department of Epidemiology
来源
Translational Psychiatry | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Schizophrenia affects >3.2 million people in the USA. However, its comorbidity patterns have not been systematically characterized in real-world populations. To address this gap, we conducted an observational study using a cohort of 86 million patients in a nationwide health insurance dataset. We identified participants with schizophrenia and those without schizophrenia matched by age, sex, and the first three digits of zip code. For each phenotype encoded in phecodes, we compared their prevalence in schizophrenia patients and the matched non-schizophrenic participants, and we performed subgroup analyses stratified by age and sex. Results show that anxiety, posttraumatic stress disorder, and substance abuse commonly occur in adolescents and young adults prior to schizophrenia diagnoses. Patients aged 60 and above are at higher risks of developing delirium, alcoholism, dementia, pelvic fracture, and osteomyelitis than their matched controls. Type 2 diabetes, sleep apnea, and eating disorders were more prevalent in women prior to schizophrenia diagnosis, whereas acute renal failure, rhabdomyolysis, and developmental delays were found at higher rates in men. Anxiety and obesity are more commonly seen in patients with schizoaffective disorders compared to patients with other types of schizophrenia. Leveraging a large-scale insurance claims dataset, this study identified less-known comorbidity patterns of schizophrenia and confirmed known ones. These comorbidity profiles can guide clinicians and researchers to take heed of early signs of co-occurring diseases.
引用
收藏
相关论文
共 213 条
[1]  
Schultz SH(2007)Schizophrenia: a review Am Fam Physician 75 1821-9
[2]  
North SW(2014)Schizophrenia: overview and treatment options Pharm Therapeutics 39 638-71
[3]  
Shields CG(2016)The economic burden of schizophrenia in the United States in 2013 J Clin psychiatry 77 764-8
[4]  
Patel KR(2013)Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration? Psychopathology 46 241-403
[5]  
Cherian J(2000)Defining the schizophrenia phenotype Curr psychiatry Rep. 2 398-52
[6]  
Gohil K(2020)Examining the use of real‐world evidence in the regulatory process Clin Pharmacol Therapeutics 107 843-7
[7]  
Atkinson D(2016)Real-world evidence—what is it and what can it tell us N. Engl J Med 375 2293-10
[8]  
Cloutier M(2010)PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations Bioinformatics 26 1205-73
[9]  
Aigbogun MS(2016)Phenome-wide association studies as a tool to advance precision medicine Annu Rev Genomics Hum Genet 17 353-45
[10]  
Guerin A(2016)Unravelling the human genome-phenome relationship using phenome-wide association studies Nat Rev Genet 17 129-65